Skip to main content
SpringerLink
Log in

S100A6 as a Potential Serum Prognostic Biomarker and Therapeutic Target in Gastric Cancer

  • Original Article
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

Background

Increased expression of S100A6 in many cancer tissues and its association with tumor behavior and patient prognosis were demonstrated, and there are no studies analyzing the serum levels of S100A6 in patients with gastric cancer (GC).

Aim

Serum S100A6 levels were investigated as a marker of tumor aggressiveness in patients with GC, and the S100A6 gene was examined as a potential therapeutic target in GC.

Methods

Serum S100A6 levels were detected in 103 GC patients and 72 healthy subjects by ELISA. Clinicopathological features of GC patients were analyzed in correlation to serum S100A6 levels. Two small interfering RNAs against S100A6 (siRNA1-S100A6 and siRNA2-S100A6) were generated and transfected into SGC7901 cells using pSUPER gfp-neo vector, and the effects of S100A6 knockdown on cell proliferation, invasion and apoptosis were evaluated in vitro. The effects of S100A6 silencing on tumor growth and metastasis were evaluated in vivo in a pseudo-metastatic GC nude mouse model.

Results

Serum S100A6 levels were significantly higher in GC patients than in healthy controls (P < 0.001). Serum S100A6 levels were significantly correlated with lymph node metastasis, TNM stage, perineural invasion and vascular invasion. Serum S100A6 level was an independent predictor of overall survival. SiRNA-mediated silencing of S100A6 significantly induced apoptosis and decreased proliferation, clone formation and the invasiveness of GC SGC7901 cells in vitro and significantly reduced tumor volume and number in vivo (P < 0.01).

Conclusion

Serum S100A6 level may serve as a potential prognostic biomarker in GC. Inhibition of S100A6 decreased the metastatic potential of GC cells.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Pisani P, Parkin DM, Bray F, Ferlay J. Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer. 1999;83:18–29.

    Article  CAS  PubMed  Google Scholar 

  2. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study. Lancet. 1997;349:1498–1504.

    Article  CAS  PubMed  Google Scholar 

  3. Meyerhardt JA, Fuchs CS. Chemotherapy options for gastric cancer. Semin Radiat Oncol. 2002;12:176–186.

    Article  PubMed  Google Scholar 

  4. Kwon HC, Kim SH, Oh SY, et al. Clinicopathologic significance of expression of nuclear factor-κB RelA and its target gene products in gastric cancer patients. World J Gastroenterol. 2012;18:4744–4750.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  5. Cross SS, Hamdy FC, Deloulme JC, Rehman I. Expression of S100 proteins in normal human tissues and common cancers using tissue microarrays: S100A6, S100A8, S100A9 and S100A11 are all overexpressed in common cancers. Histopathology. 2005;46:256–269.

    Article  CAS  PubMed  Google Scholar 

  6. Lesniak W, Slomnicki LP, Filipek A. S100A6-new facts and features. Biochem Biophys Res Commun. 2009;390:1087–1092.

    Article  CAS  PubMed  Google Scholar 

  7. Tonini GP, Fabretti G, Kuznicki J, et al. Gene expression and protein localisation of calcyclin, a calcium-binding protein of the S-100 family in fresh neuroblastomas. Eur J Cancer. 1995;31A:499–504.

    Article  CAS  PubMed  Google Scholar 

  8. Sofiadis A, Dinets A, Orre LM, et al. Proteomic study of thyroid tumors reveals frequent up-regulation of the Ca2+-binding protein S100A6 in papillary thyroid carcinoma. Thyroid. 2010;20:1067–1076.

    Article  CAS  PubMed  Google Scholar 

  9. Luu HH, Zhou L, Haydon RC, et al. Increased expression of S100A6 is associated with decreased metastasis and inhibition of cell migration and anchorage independent growth in human osteosarcoma. Cancer Lett. 2005;229:135–148.

    Article  CAS  PubMed  Google Scholar 

  10. Kim J, Kim J, Yoon S, et al. Choe I.S100A6 protein as a marker for differential diagnosis of cholangiocarcinoma from hepatocellular carcinoma. Hepatol Res. 2002;23:274.

    Article  PubMed  Google Scholar 

  11. Vimalachandran D, Greenhalf W, Thompson C, et al. High nuclear S100A6 (Calcyclin) is significantly associated with poor survival in pancreatic cancer patients. Cancer Res. 2005;65:3218–3225.

    CAS  PubMed  Google Scholar 

  12. Ohuchida K, Mizumoto K, Ishikawa N, et al. The role of S100A6 in pancreatic cancer development and its clinical implication as a diagnostic marker and therapeutic target. Clin Cancer Res. 2005;11:7785–7793.

    Article  CAS  PubMed  Google Scholar 

  13. Yang YQ, Zhang LJ, Dong H, et al. Upregulated expression of S100A6 in human gastric cancer. J Dig Dis. 2007;8:186–193.

    Article  CAS  PubMed  Google Scholar 

  14. Wang XH, Zhang LH, Zhong XY, et al. S100A6 overexpression is associated with poor prognosis and is epigenetically up-regulated in gastric cancer. Am J Pathol. 2010;177:586–597.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  15. Chen D, Jiao XL, Liu ZK, Zhang MS, Niu M. Knockdown of PLA2G2A sensitizes gastric cancer cells to 5-FU in vitro. Eur Rev Med Pharmacol Sci. 2013;17:1703–1708.

    CAS  PubMed  Google Scholar 

  16. Ohuchida K, Mizumoto K, Ishikawa N, et al. The role of S100A6 in pancreatic cancer development and its clinical implication as a diagnostic marker and therapeutic target. Clin Cancer Res. 2005;11:7785–7793.

    Article  CAS  PubMed  Google Scholar 

  17. Luo X, Sharff KA, Chen J, He TC, Luu HH. S100A6 expression and function in human osteosarcoma. Clin Orthop Relat Res. 2008;466:2060–2070.

    Article  PubMed Central  PubMed  Google Scholar 

  18. Tsoporis JN, Izhar S, Parker TG. Expression of S100A6 in cardiac myocytes limits apoptosis induced by tumor necrosis factor-alpha. J Biol Chem. 2008;283:30174–30183.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

Download references

Acknowledgments

Authors received grant support from National Natural Science Foundation of China (No. 81370567).

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Department of General Surgery, The Affiliated Hospital of Qingdao University, No. 16, Jiangsu Road, Qingdao, 266509, Shandong, China

    Jianli Zhang, Kejun Zhang & Jian Zhang

  2. Department of Nutrition, The Affiliated Hospital of Qingdao University, Qingdao, 266509, Shandong, China

    Kejun Zhang & Xiuli Jiang

Authors
  1. Jianli Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kejun Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Xiuli Jiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jian Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jianli Zhang.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zhang, J., Zhang, K., Jiang, X. et al. S100A6 as a Potential Serum Prognostic Biomarker and Therapeutic Target in Gastric Cancer. Dig Dis Sci 59, 2136–2144 (2014). https://doi.org/10.1007/s10620-014-3137-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-014-3137-z

Keywords

Search

Navigation